Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2015

Open Access 01-12-2015 | Research article

Monitoring patients on chronic treatment with antidepressants between 2003 and 2011: analysis of factors associated with compliance

Authors: M. Catalina Serna, Jordi Real, Inés Cruz, Leonardo Galván, Elisabet Martin

Published in: BMC Public Health | Issue 1/2015

Login to get access

Abstract

Background

Clinical practice guidelines consider the use of antidepressants as one of the standard treatments for anxiety disorders, due to the significant improvements obtained in quality of life and functional disability. In addition, in patients who have not achieved a favorable response after 3 months of psychotherapy, antidepressants are recommended as part of a combined treatment approach. This combination with psychotropic drugs and psychotherapy appears to be indicated from baseline in patients with moderate, severe or recurrent depression. In the last decade, antidepressant prescription rates in general practice have increased between 4 and 10 times. Depression presents high rates of relapse and recurrence. Treatment is often interrupted prematurely, leading to increases in both relapse rates and health care costs. Few studies have analysed the chronic use of antidepressant drugs and long-term adherence. Objective: To evaluate compliance with antidepressant treatment between 2003 and 2011 and to explore the associated factors.

Methods

Retrospective cohort study of antidepressant dispensing. Setting: Health Region of Lleida between 2003 and 2011. Participants: Patients with chronic prescription of antidepressants (ATC code NO6A) during 2003 were followed up until December 2011. The sample comprised 3684 subjects. Main measures: The compliance rate was calculated on the basis of the number of units withdrawn from the pharmacy and the theoretical number of units required according to the scheduled duration of treatment: compliance was defined in cases with scores greater than or equal to 80 %.

Results

12.5 % of patients received chronic antidepressant treatment for at least 4 years. Mean age was 54 years, and 73.2 % of patients were female. Almost a third (32.4 %) presented anxiety disorders and 26.5 % mood disorders. The overall compliance rate was 22 % (28 % in patients with depression, and 21 % in patients with anxiety). According to gender, compliance rates were 21.4 % for males and 22.4 % for females. Compliance was more likely in patients with polypharmacy.

Conclusions

One in 4 patients complied with treatment. Factors associated with better compliance were polypharmacy and diagnosis of depressive or mixed anxiety-depressive disorder.
Literature
1.
Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010. Lancet. 2012;380:2197–223.CrossRefPubMed
2.
Ferrari AJ, Charlson FJ, Norman RE, Flaxman AD, Patten SB, Vos T, et al. The epidemiological modelling of major depressive disorder: application for the Global Burden of Disease Study 2010. PLoS One. 2013;8(7):e69637.PubMedCentralCrossRefPubMed
3.
Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382(9904):1575–86. doi:10.​1016/​S0140-6736(13)61611-6. Epub 2013 Aug 29.CrossRefPubMed
4.
Baxter AJ, Scott KM, Vos T, Whiteford HA. Global prevalence of anxiety disorders: a systematic review and meta-regression. Psychol Med. 2013;43(5):897–910.CrossRefPubMed
5.
López-Ibor JJ, Alonso J, Haro JM. Estudio Europeo de la Epidemiología de los Trastornos Mentales (ESEMeD): aportaciones para la salud mental en España. Actas Esp Psiquiatr. 2007;35 Suppl 2:1–3.PubMed
6.
Haro JM, Palacín C, Vilagut G, Martínez M, Bernal M, Luque I, et al. Prevalencia de los trastornos mentales y factores asociados: resultados del estudio ESEMeDEspaña. Med Clin (Barc). 2006;126(12):445–51.CrossRef
7.
8.
NICE. Depression. Treatment and management of depression in adults, including adults with a chronic physical health problem: National Clinical Practice Guideline number 23 (update); October 2009.
9.
Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095.CrossRefPubMed
10.
Katon W, Ciechanowski P. Initial treatment of depression in adults. In: Basow DS, editor. UpToDate. Waltham, MA: UpToDate; 2009.
11.
Jureidini J, Tonkin A. Overuse of antidepressant drugs for the treatment of depression. CNS Drugs. 2006;20(8):623–32.CrossRefPubMed
12.
Tylee A, Walters P. Underrecognition of anxiety and mood disorders in primary care: why does the problem exist and what can be done? J Clin Psychiatry. 2007;68 Suppl 2:27–30.PubMed
13.
Spijker J, de Graaf R, Bijl RV, Beekman AT, Ormel J, Nolen WA. Duration of major depressive episodes in the general population: results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Br J Psychiatry. 2002;181:208–13.CrossRefPubMed
14.
Khandker RK, Kruzikas DT, McLaughlin TP. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder. J Manag Care Pharm. 2008;14:426–41.PubMed
15.
Lin EH, Von Korff M, Bush T, Simon GE, Walker E, Robinson P. The role of the primary care physician in patients’ adherence to antidepressant therapy. Med Care. 1995;33:67–74.CrossRefPubMed
16.
17.
Rollason V, Vogt N. Reduction of polypharmacy in the elderly: a systematic review of the role of the pharmacist. Drugs Aging. 2003;20:817–32.CrossRefPubMed
18.
Serna MC, Cruz I, Real J, Gascó E, Galván L. Duration and adherence of antidepressant treatment (2003 to 2007) based on a prescription database. Eur Psychiatry. 2010;25:206–13.CrossRefPubMed
19.
ATC Index with DDDs. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 1999).
20.
Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44–7.CrossRefPubMed
21.
Keller MB, Boland RJ. The implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol Psychiatry. 1998;44:348–60.CrossRefPubMed
22.
World Health Organization. International classification of diseases and related health problems, 10th revision. Geneva: VHO; 1992.
23.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. [tex. rev.]. Washington, DC: American Psychiatric Association; 2000.
24.
Hyman SE. The diagnosis of mental disorders: The problem of reification. Annu Rev Clin Psychol. 2010;6:155–79.CrossRefPubMed
25.
First MB. Clinical utility in the revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM). Prof Psychol. 2010;41:465–73.CrossRef
26.
Reed GM, Ayuso-Mateos JL. Hacia una clasificación internacional de los Trastornos Mentales de la OMS de mayor utilidad clínica. Rev Psiquiatr Salud Ment (Barc). 2011;4(3):113–6.CrossRef
27.
Macdonald S, Morrison J, Maxwell M, Munoz-Arroyo R, Power A, Smith M, et al. ‘A coal face option’: GPs’ perspectives on the rise in antidepressant prescribing. Br J Gen Pract. 2009;59(566):e299–307.PubMedCentralCrossRefPubMed
28.
Barlow DH, Allen LB, Choate ML. Toward a unified treatment for emotional disorders. Behav Ther. 2004;35:205–30.CrossRef
29.
Gualano MR, Bert F, Mannocci A, La Torre G, Zeppegno P, Siliquini R. Consumption of antidepressants in Italy: recent trends and their significance for public health. Psychiatr Serv. 2014;65(10):1226–31.CrossRefPubMed
30.
Serna Arnáiz C, Galván Santiago L, Gascó Eguíluz E, Santafé Soler P, Martín Gracia E, Vila PT. Evolución en el consumo de antidepresivos durante los años 2002 a 2004. Aten Primaria. 2006;38(8):456–60.CrossRefPubMed
31.
Martín Gómez MC, González Parra D, Franco Romo P, Sánchez IS. Protocolo terapéutico de la depresión crónica. Medicine. 2007;9(85):5503–6.
32.
Institute for Clinical Systems Improvement (ICSI). Health care guideline: major depression in adults in primary care. 9th ed. Bloomington: Institute for Clinical Systems Improvement; (ICSI); 2004.
33.
Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361(9358):653–61.CrossRefPubMed
34.
Reimherr FW, Amsterdam JD, Quitkin FM, Rosenbaum JF, Fava M, Zajecka J, et al. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry. 1998;155(9):1247–53.CrossRefPubMed
35.
Burton C, Anderson N, Wilde K, Simpson CR. Factors associated with duration of new antidepressant treatment: a large database study. Br J Gen Pract. 2012;62(595):104–12.CrossRef
36.
Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry. 2007;62:1217–27.CrossRefPubMed
37.
Ley 14/1986 de 25 de abril, Ley General de Sanidad. BOE núm. 112 de 24/4/86.
Metadata
Title
Monitoring patients on chronic treatment with antidepressants between 2003 and 2011: analysis of factors associated with compliance
Authors
M. Catalina Serna
Jordi Real
Inés Cruz
Leonardo Galván
Elisabet Martin
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2015
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-015-2493-8

Other articles of this Issue 1/2015

BMC Public Health 1/2015 Go to the issue

Research article

Does workplace health promotion contribute to job stress reduction? Three-year findings from Partnering Healthy@Work

Research article

Descriptive study of sedentary behaviours in 35,444 French working adults: cross-sectional findings from the ACTI-Cités study

Research article

An application in identifying high-risk populations in alternative tobacco product use utilizing logistic regression and CART: a heuristic comparison

Research article

Progress and challenges in implementing HIV care and treatment policies in Latin America following the treatment 2.0 initiative

Research article

Mortality among drowning rescuers in China, 2013: a review of 225 rescue incidents from the press

Research article

Use of electronic cigarettes among Romanian university students: a cross-sectional study